Toggle navigation
About Us
Science & Innovation
Products and Resources
Our Responsibility
Careers
Investors
Media
Toggle navigation
Press Releases
Featured News
Press Statements
Subscribe
Media Contacts
Press Releases
Month Year
Su
Mo
Tu
We
Th
Fr
Sa
25
26
27
28
29
30
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
1
2
3
4
5
Cancel
Go
Month Year
Su
Mo
Tu
We
Th
Fr
Sa
25
26
27
28
29
30
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
1
2
3
4
5
Cancel
Go
Year
All Years
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
Category
All Categories
Corporate News
Product News
Vaccines News
Uncategorized
Keywords
Go
Advanced Search
Search
Search Headlines Only
Category
All Categories
Corporate News
Product News
Vaccines News
Uncategorized
From
To
Asset Types
Video
Audio
Photos
Documents
Events
Standard
Jun 2, 2022
Sanofi grants Regeneron worldwide exclusive license rights to Libtayo® (cemiplimab-rwlc)
Sanofi will receive an upfront payment of $900 million, and an 11% royalty on worldwide net sales of Libtayo
Jun 1, 2022
FDA grants efanesoctocog alfa Breakthrough Therapy designation for hemophilia A
Efanesoctocog alfa is the first factor VIII therapy to be awarded Breakthrough Therapy designation by the FDA
May 31, 2022
FDA accepts Dupixent® (dupilumab) for priority review in adults with prurigo nodularis
May 20, 2022
FDA approves Dupixent® (dupilumab) as first treatment for adults and children aged 12 and older with eosinophilic esophagitis
May 17, 2022
New data from fast-growing innovative Oncology pipeline and portfolio to be presented at 2022 ASCO Annual Meeting
Data to be shared across multiple tumor types, including multiple myeloma, lung cancer and breast cancer
Show
5
10
25
50
100
per page
«
1
…
6
7
8
9
10
11
12
…
189
»
Print
Email page
RSS